What is a good choice of antihypertensive medication for a patient with stage 2 hypertension (blood pressure 139/113 mmHg) already taking lisinopril (angiotensin-converting enzyme inhibitor) 10 mg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Stage 2 Hypertension with Blood Pressure 139/113 mmHg in a Patient Already Taking Lisinopril 10 mg

For a patient with stage 2 hypertension (BP 139/113 mmHg) already taking lisinopril 10 mg, adding a long-acting dihydropyridine calcium channel blocker (CCB) such as amlodipine is the best next step in management.

Rationale for Adding a Calcium Channel Blocker

The current blood pressure reading of 139/113 mmHg indicates inadequate control on lisinopril 10 mg monotherapy. According to the most recent guidelines:

  • The 2024 ESC guidelines recommend combination therapy for most patients with confirmed hypertension, with preferred combinations being a RAS blocker (ACE inhibitor or ARB) with either a dihydropyridine CCB or diuretic 1.
  • When blood pressure is not controlled on monotherapy, adding a second agent from a different class is recommended rather than simply increasing the dose of the first medication 1.
  • The patient is already on an ACE inhibitor (lisinopril), making a dihydropyridine CCB the logical next addition.

Medication Selection Algorithm

  1. First step (current): ACE inhibitor (lisinopril 10 mg)
  2. Second step (recommended): Add long-acting dihydropyridine CCB (amlodipine 5 mg)
  3. Third step (if needed later): Add thiazide/thiazide-like diuretic if BP remains uncontrolled

Benefits of Adding a CCB to Lisinopril

  • The combination of an ACE inhibitor and CCB has shown superior efficacy compared to monotherapy with either agent 2, 3.
  • In a randomized crossover study, the combination of lisinopril and amlodipine demonstrated significant additional blood pressure-lowering effects compared to either drug alone 3.
  • This combination provides complementary mechanisms of action:
    • Lisinopril blocks the renin-angiotensin system
    • Amlodipine causes peripheral vasodilation through calcium channel blockade

Dosing Considerations

  • Start with amlodipine 5 mg once daily
  • The combination of low-dose amlodipine (2.5 mg) with lisinopril (5 mg) has been shown to produce significant blood pressure lowering in a higher percentage of patients than individual low-dose therapy 2.
  • If blood pressure remains uncontrolled after 2-4 weeks, consider:
    1. Increasing amlodipine to 10 mg
    2. Increasing lisinopril to 20-40 mg
    3. Adding a thiazide diuretic as a third agent

Monitoring Recommendations

  • Recheck blood pressure in 2-4 weeks after adding amlodipine
  • Monitor for potential side effects:
    • Peripheral edema (from CCB)
    • Dizziness from enhanced blood pressure lowering
    • Electrolytes and renal function

Alternative Approaches

If a CCB is contraindicated or not tolerated, a thiazide or thiazide-like diuretic would be an appropriate alternative second agent 1.

Special Considerations

  • The patient's current diastolic BP of 113 mmHg indicates urgent need for better control to reduce cardiovascular risk
  • Single-pill combinations of ACE inhibitor and CCB should be considered once doses are stabilized to improve adherence 1, 4
  • If BP remains uncontrolled on triple therapy (ACE inhibitor + CCB + diuretic), adding spironolactone should be considered 1

Common Pitfalls to Avoid

  • Avoid simply increasing the lisinopril dose without adding a second agent, as combination therapy is more effective than high-dose monotherapy
  • Avoid non-dihydropyridine CCBs (verapamil, diltiazem) if the patient has heart failure or conduction abnormalities
  • Avoid combining two RAS blockers (such as adding an ARB to the ACE inhibitor), as this is not recommended due to increased adverse effects without additional benefit 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Hypertension

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.